tiprankstipranks
Advertisement
Advertisement

URGN Stock Latest News

UroGen Pharma initiated with a Buy at Jefferies
The FlyUroGen Pharma initiated with a Buy at Jefferies
3d ago
URGN
UroGen Pharma publishes results from ENVISION trial of Zusduri
PremiumThe Fly
UroGen Pharma publishes results from ENVISION trial of Zusduri
13d ago
URGN
UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report
PremiumThe Fly
UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report
1M ago
URGN
Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
PremiumRatings
Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
1M ago
URGN
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
PremiumCompany Announcements
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
1M ago
URGN
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
PremiumRatingsUroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
1M ago
URGN
Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk
Premium
Company Announcements
Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk
1M ago
URGN
UroGen Pharma Secures New $250 Million Term Loan
Premium
Company Announcements
UroGen Pharma Secures New $250 Million Term Loan
1M ago
8K
URGN
UroGen Pharma reports Q4 EPS (54c), consensus (51c)
PremiumThe Fly
UroGen Pharma reports Q4 EPS (54c), consensus (51c)
1M ago
URGN
UroGen Pharma sees FY26 net sales for Jelmyto $97M-$101M
PremiumThe Fly
UroGen Pharma sees FY26 net sales for Jelmyto $97M-$101M
1M ago
URGN
UroGen Pharma announces refinanced term loan agreement with Pharmakon
PremiumThe Fly
UroGen Pharma announces refinanced term loan agreement with Pharmakon
1M ago
URGN
URGN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
URGN Upcoming Earnings Report: What to Expect?
1M ago
URGN
UroGen Pharma announces post-hoc analyses from Phase 3 trial of Zusduri
PremiumThe FlyUroGen Pharma announces post-hoc analyses from Phase 3 trial of Zusduri
1M ago
URGN
UroGen’s Phase 1 UGN-301 Bladder Cancer Trial Completion: What Investors Should Watch Next
Premium
Company Announcements
UroGen’s Phase 1 UGN-301 Bladder Cancer Trial Completion: What Investors Should Watch Next
3M ago
URGN
UroGen Pharma says permanent J Code for ZUSDURI now in effect
Premium
The Fly
UroGen Pharma says permanent J Code for ZUSDURI now in effect
3M ago
URGN
UroGen Pharma announces inducement grants under Nasdaq listing rule
PremiumThe Fly
UroGen Pharma announces inducement grants under Nasdaq listing rule
4M ago
URGN
UroGen Pharma’s Promising Outlook: Buy Rating Backed by ZUSDURI’s Growth and Strong Financial Health
PremiumRatings
UroGen Pharma’s Promising Outlook: Buy Rating Backed by ZUSDURI’s Growth and Strong Financial Health
5M ago
URGN
UroGen Pharma’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
UroGen Pharma’s Earnings Call: Growth Amid Challenges
5M ago
URGN
UroGen Pharma’s ZUSDURI Launch Drives Q3 Growth
PremiumCompany Announcements
UroGen Pharma’s ZUSDURI Launch Drives Q3 Growth
5M ago
URGN
UroGen Pharma files automatic mixed securities shelf
PremiumThe FlyUroGen Pharma files automatic mixed securities shelf
5M ago
URGN
Urogen Pharma’s Promising Growth and Demand Surge Support Buy Rating
Premium
Ratings
Urogen Pharma’s Promising Growth and Demand Surge Support Buy Rating
5M ago
URGN
UroGen Pharma reports Q3 EPS (69c), consensus (68c)
Premium
The Fly
UroGen Pharma reports Q3 EPS (69c), consensus (68c)
5M ago
URGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >